ACADIA PHARMACEUTICALS INC. Financing Cash Flow
ACADIA PHARMACEUTICALS INC. (ACAD) reported Financing Cash Flow of $14.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $10.49M, a 34.23% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.23M, a 130.20% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $22.67M, a 1051.14% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $9.42M, a 3416.04% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2025 was $49.88M, a 628.75% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2024 was $6.84M, a 72.76% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2023 was $25.13M, a 206.49% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2022 was $8.20M, a 54.86% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $14.72M 10-Q · filed 2026-08-05 | $37.39M derived: sum of 3 quarters · filed 2026-08-05 | $46.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.23M 10-Q · filed 2026-05-07 | $26.90M derived: sum of 2 quarters · filed 2026-05-07 | $36.32M derived: sum of 3 quarters · filed 2026-05-07 | $52.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $22.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.09M derived: sum of 2 quarters · filed 2026-02-26 | $48.05M derived: sum of 3 quarters · filed 2026-08-05 | $49.88M 10-K · filed 2026-02-26 |
| 2025-09-30 | $9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $25.38M derived: sum of 2 quarters · filed 2026-08-05 | $27.22M 10-Q · filed 2025-11-06 | $29.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $15.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $17.79M 10-Q · filed 2026-08-05 | $19.76M derived: sum of 3 quarters · filed 2026-08-05 | $20.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.84M 10-Q · filed 2026-05-07 | $3.81M derived: sum of 2 quarters · filed 2026-05-07 | $4.08M derived: sum of 3 quarters · filed 2026-05-07 | $7.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.24M derived: sum of 2 quarters · filed 2026-02-26 | $5.80M derived: sum of 3 quarters · filed 2026-02-26 | $6.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.83M derived: sum of 2 quarters · filed 2025-11-06 | $4.88M 10-Q · filed 2025-11-06 | $10.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.61M 10-Q · filed 2025-08-07 | $10.04M derived: sum of 3 quarters · filed 2026-02-26 | $22.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-08 | $6.48M derived: sum of 2 quarters · filed 2026-02-26 | $19.23M derived: sum of 3 quarters · filed 2026-02-26 | $24.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.18M derived: sum of 2 quarters · filed 2026-02-26 | $23.66M derived: sum of 3 quarters · filed 2026-02-26 | $25.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $12.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $18.23M derived: sum of 2 quarters · filed 2024-11-07 | $19.70M 10-Q · filed 2024-11-07 | $21.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $6.94M 10-Q · filed 2024-08-07 | $8.56M derived: sum of 3 quarters · filed 2025-02-27 | $8.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.47M 10-Q · filed 2024-05-09 | $3.08M derived: sum of 2 quarters · filed 2025-02-27 | $3.37M derived: sum of 3 quarters · filed 2025-02-27 | $7.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.90M derived: sum of 2 quarters · filed 2025-02-27 | $5.73M derived: sum of 3 quarters · filed 2025-02-27 | $8.20M 10-K · filed 2025-02-27 |
| 2022-09-30 | $287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.12M derived: sum of 2 quarters · filed 2023-11-03 | $6.58M 10-Q · filed 2023-11-03 | $10.95M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $6.30M 10-Q · filed 2023-08-03 | $10.66M derived: sum of 3 quarters · filed 2024-02-28 | $11.73M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.47M 10-Q · filed 2023-05-08 | $6.83M derived: sum of 2 quarters · filed 2024-02-28 | $7.90M derived: sum of 3 quarters · filed 2024-02-28 | $12.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.43M derived: sum of 2 quarters · filed 2024-02-28 | $10.44M derived: sum of 3 quarters · filed 2024-02-28 | $18.16M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.07M derived: sum of 2 quarters · filed 2022-11-03 | $13.80M 10-Q · filed 2022-11-03 | $31.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $12.73M 10-Q · filed 2022-08-09 | $30.86M derived: sum of 3 quarters · filed 2023-02-28 | $42.57M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $7.73M 10-Q · filed 2022-05-05 | $25.85M derived: sum of 2 quarters · filed 2023-02-28 | $37.57M derived: sum of 3 quarters · filed 2023-02-28 | $84.97M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $18.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $29.84M derived: sum of 2 quarters · filed 2023-02-28 | $77.24M derived: sum of 3 quarters · filed 2023-02-28 | $81.00M 10-K · filed 2023-02-28 |
| 2020-09-30 | $11.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $59.12M derived: sum of 2 quarters · filed 2021-11-09 | $62.87M 10-Q · filed 2021-11-09 | $105.93M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $47.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $51.16M 10-Q · filed 2021-08-05 | $94.21M derived: sum of 3 quarters · filed 2022-03-01 | $414.18M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $3.75M 10-Q · filed 2021-05-06 | $46.81M derived: sum of 2 quarters · filed 2022-03-01 | $366.78M derived: sum of 3 quarters · filed 2022-03-01 | $371.43M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $43.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $363.02M derived: sum of 2 quarters · filed 2022-03-01 | $367.67M derived: sum of 3 quarters · filed 2022-03-01 | $371.85M 10-K · filed 2022-03-01 |
| 2019-09-30 | $319.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $324.61M derived: sum of 2 quarters · filed 2020-11-04 | $328.79M 10-Q · filed 2020-11-04 | $629.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $4.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $8.82M 10-Q · filed 2020-08-06 | $309.43M derived: sum of 3 quarters · filed 2021-02-25 | $309.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $4.18M 10-Q · filed 2020-05-08 | $304.78M derived: sum of 2 quarters · filed 2021-02-25 | $304.99M derived: sum of 3 quarters · filed 2021-02-25 | $307.94M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $300.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $300.81M derived: sum of 2 quarters · filed 2021-02-25 | $303.77M derived: sum of 3 quarters · filed 2021-02-25 | $306.65M 10-K · filed 2021-02-25 |
| 2018-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.16M derived: sum of 2 quarters · filed 2019-10-31 | $6.04M 10-Q · filed 2019-10-31 | $10.84M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $5.83M 10-Q · filed 2019-08-01 | $10.62M derived: sum of 3 quarters · filed 2020-02-27 | $18.52M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.88M 10-Q · filed 2019-05-02 | $7.67M derived: sum of 2 quarters · filed 2020-02-27 | $15.57M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $12.69M derived: sum of 2 quarters · filed 2020-02-27 | $31.19M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $7.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $26.40M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $18.50M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $533.81M 10-K · filed 2019-02-27 | |||
| 2013-03-31 | $208.00K 10-Q · filed 2013-05-07 | $91.44M derived: sum of 2 quarters · filed 2013-05-07 | $98.30M derived: sum of 3 quarters · filed 2013-05-07 | $98.36M derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-12-31 | $91.23M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $98.09M derived: sum of 2 quarters · filed 2013-03-12 | $98.15M derived: sum of 3 quarters · filed 2013-03-12 | $98.17M 10-K · filed 2013-03-12 |
| 2012-09-30 | $6.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $6.92M derived: sum of 2 quarters · filed 2012-11-05 | $6.94M 10-Q · filed 2012-11-05 | $7.04M derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $79.00K 10-Q · filed 2012-08-08 | $176.00K derived: sum of 3 quarters · filed 2013-05-07 | $166.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2012-03-31 | $22.00K 10-Q · filed 2013-05-07 | $119.00K derived: sum of 2 quarters · filed 2013-05-07 | $109.00K derived: sum of 3 quarters · filed 2013-05-07 | $156.00K derived: sum of 4 quarters · filed 2013-05-07 |
| 2011-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $87.00K derived: sum of 2 quarters · filed 2013-03-12 | $134.00K derived: sum of 3 quarters · filed 2013-03-12 | $13.94M 10-K · filed 2013-03-12 |
| 2011-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | $37.00K derived: sum of 2 quarters · filed 2012-11-05 | $13.85M 10-Q · filed 2012-11-05 | $14.21M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $13.86M 10-Q · filed 2012-08-08 | $14.22M derived: sum of 3 quarters · filed 2013-03-12 | $14.53M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $13.81M 10-Q · filed 2012-05-08 | $14.17M derived: sum of 2 quarters · filed 2013-03-12 | $14.49M derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | $359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $677.00K derived: sum of 2 quarters · filed 2013-03-12 | $470.00K 10-K · filed 2013-03-12 | |
| 2010-09-30 | $318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $111.00K 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$207.00K 10-Q · filed 2011-08-10 | |||
| 2009-12-31 | $1.16M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |